NewAmsterdam Pharma Company N.V.

Major stakeholders currently include Frazier Life Sciences Management, L.P. ($542.4M), Capital World Investors ($355.6M), Ra Capital Management, L.p. ($305.7M). Based on the latest 13F filings, there are a total of 170 tracked investment funds and institutions maintaining positions in NAMS.

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $219.4M, driven by 88 managers accumulating shares while 83 reduced their exposure.

In the latest period, 48 funds trimmed their holdings, and 35 managers completely exited their positions. The aggregate reported sell value was $934.3M.

Yes, buying activity remains notable. 20 institutions opened new positions in {ticker}, and 68 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.6B.